Lakewood-Amedex Biotherapeutics Inc. — fact timeline
Source-grounded facts extracted from Lakewood-Amedex Biotherapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lakewood-Amedex Biotherapeutics Inc.: Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000 (effective 2026-06-19).
“On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).”
Joseph Tucker was appointed as Director at Lakewood-Amedex Biotherapeutics Inc..
“On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.